TIOTROPIUM AND OLODATEROL IN THE PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS: DYNAGITO STUDY DATA

Abstract

Symptomatic exacerbations are frequently reported by patients with chronic obstructive pulmonary disease (COPD). Combinations of long-acting bronchodilators are recommended to reduce the rate of chronic obstructive pulmonary disease exacerbations. It is unclear whether combining olodaterol, a long-acting beta-agonist (LABA), with tiotropium, a long-acting anti-muscarinic (LAMA), reduces the rate of exacerbations compared with tiotropium alone. DYNAGITO trial is the first of its kind to address the question of whether adding a LABA to tiotropium can offer further benefits in terms ofreducing exacerbations in patients with COPD. Overall, 9009 patients were screened from 818 centres in 51 countries. The rate of moderate and severe exacerbations was lower with tiotropium–olodaterol than tiotropium (rate ratio (RR) 0,93, 99% CI 0,85–1,02; p=0,0498), not meeting the targeted 0,01 significance level to approve superiority.